Responder analyses and the assessment of a clinically relevant treatment effect

Trials

Volumn 8, Issue , 2007, Pages

  Snapinn, Steven M ^a   Jiang, Qi ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CONTROLLED STUDY; ECONOMIC EVALUATION; GOAL ATTAINMENT; HUMAN; INTERNAL CONSISTENCY; NORMAL DISTRIBUTION; OUTCOME ASSESSMENT; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

EID: 37749015060     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-8-31     Document Type: Article

References (10)

1. Eron J Jr Yeni P Gathe J Jr Estrada V Dejesus E Staszewski S Lackey P Katlama C Young B Yau L Sutherland-Phillips D Wannamaker P Vavro C Patel L Yeo J Shaefer M for the KLEAN Study Team The KLEAN Study of Fosamprenavir-Ritonavir Versus Lopinavir-Ritonavir, Each in Combination with Abacavir-Lamivudine, for Initial Treatment of HIV Infection over 48 Weeks: A Randomised Non-Inferiority Trial Lancet 2006, 368:476-482 10.1016/S0140-6736(06)69155-1 16890834
2. Tyring S Gottlieb A Papp K Gordon K Leonardi C Wang A Lalla D Woolley M Jahreis A Zitnik R Cella D Krishnan R Etanercept and Clinical Outcomes, Fatigue, and Depression in Psoriasis: Double-Blind Placebo-Controlled Randomised Phase III Trial Lancet 2006, 367:29-35 10.1016/ S0140-6736(05)67763-X 16399150
3. Edwards JCW Szczepanski L Szechinski J Filipowicz-Sosnowska A Emery P Close DR Stevens RM Shaw T Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis New England Journal of Medicine 2004, 350:2572-2581 10.1056/NEJMoa032534 15201414
4. McMillan-Price J Petocz P Atkinson F O'Neill K Samman S Steinbeck K Caterson I Brand-Miller J Comparison of 4 Diets of Varying Glycemic Load on Weight Loss and Cardiovascular Risk Reduction in Overweight and Obese Young Adults Archives of Internal Medicine 2006, 166:1466-1475 10.1001/ archinte.166.14.1466 16864756
5. FDA Draft Guidance or Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2006
6. Committee for Medicinal Products for Human Use (CHMP) Guideline on the Choice of the Non-Inferiority Margin EMEA/CPMP/EWP/2158/99, July 27, 2005
7. Altman DG Royston P The Cost of Dichotomising Continuous Variables British Medical Journal 2006, 332:1080-1458573 16675816 10.1136/ bmj.332.7549.1080
8. Deyi BA Kosinski AS Snapinn SM Power Considerations When a Continuous Outcome Variable Is Dichotomized Journal of Biopharmaceutical Statistics 1998, 8:337-352 10.1080/10543409808835243 9598427
9. Campbell MJ Julious SA Altman DG Estimating Sample Sizes for Binary, Ordered Categorical and Continuous Outcomes in Two Group Comparisons British Medical Journal 1995, 311:1145-1148 7580713
10. Senn S Disappointing Dichotomies Pharmaceutical Statistics 2003, 2:239-240 10.1002/pst.90